Kailera to Present Phase 1 Injection and Phase 2 Oral Ribupatide Data June 7-8
KLRA•Kailera Therapeutics and Hengrui Pharma will present clinical results for oral and injectable ribupatide at the American Diabetes Association’s 86th Scientific Sessions June 5–8. Hengrui will showcase Phase 2 oral trial data in adults with obesity on June 7, while Kailera unveils Phase 1 injection bridging results on June 8.
1. Joint ADA Presentation Details
Two abstracts have been accepted for the ADA’s 86th Scientific Sessions June 5–8: Hengrui will present a Phase 2 oral ribupatide (HRS9531) efficacy and safety poster on June 7 at 12:30 p.m. CT and Kailera will present Phase 1 single-ascending dose injection (KAI-9531) data on June 8 at 12:30 p.m. CT.
2. Phase 2 Oral Ribupatide Trial
The Phase 2 oral ribupatide trial enrolled adults with obesity to assess weight loss, tolerability and safety endpoints over multiple dosing periods, with topline results from the general poster session expected to inform the potential of an oral GLP-1/GIP receptor dual agonist.
3. Phase 1 Injection Study and KaiNETIC Program
Kailera’s Phase 1 bridging injection study evaluated PK/PD profiles of KAI-9531 and supported initiation of the global Phase 3 KaiNETIC program, with initial data set to outline dose-response and safety metrics underpinning development of the once-weekly injectable.
Related News
Wise Group Plc: JP Morgan cuts target price to $17.3 from $17.5
Kioxia Holdings Corp - Strongly Disagree With Viasat’s Claims And The Verdict In This Case That Certain Kioxia Products Infringe The Single Patent Claim That Viasat Presented To The Jury
